FDA endorses bexmarilimab for higher-risk myelodysplastic syndromes, paving the way for accelerated approval and promising ...

A systemic review of patient-reported outcome measures used in melanoma research and clinical practice reveals high ...

Patient dosing has continued to successfully escalate in an early-phase trial of a novel FSHR-targeting CAR T-cell therapy in ...

Zev A. Wainberg, MD, discussed the significance of the AMPLIFY-201 trial, next steps for this vaccine platform, and the signs ...

The FDA designates iza-bren as a breakthrough therapy for advanced EGFR-mutant NSCLC, promising improved outcomes for ...

FDA designates ifinatamab deruxtecan as a breakthrough therapy for extensive-stage small cell lung cancer, promising improved ...

Jered Haddad transforms his cancer journey into a mission, cycling in Iceland to raise awareness and funds for multiple ...

Neoadjuvant immunotherapy combined with chemotherapy shows promising results in treating limited-stage small cell lung cancer ...

Explore the evolving treatment landscape of chronic myeloid leukemia with asciminib, a promising new TKI showing high ...

FDA fast-tracks HLD-0915, a novel therapy for metastatic castration-resistant prostate cancer, promising rapid development ...

New analysis reveals enzalutamide significantly outperforms darolutamide in treating metastatic hormone-sensitive prostate ...

Pembrolizumab showed an 89% objective response rate in unresectable desmoplastic melanoma, with a 37% complete response rate.